Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | PYGL | P06737 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600037 | 0.85 | MAPT (0.69) | KDM4EMAPTMAPK1HTTLMNA | |
| SCHEMBL4509606 | 0.80 | MAPT (0.50) | KDM4EMAPTMAPK1L3MBTL1FFAR1 | |
| SCHEMBL27654243 | 0.79 | MAPT (0.77) | KDM4EMAPTMAPK1HTTLMNA | |
| SCHEMBL14631866 | 0.78 | NR3C1 (0.46) | KMT2ANR1H4MAPK14RXRARXRB | |
| SCHEMBL11162636 | 0.77 | ALDH1A1 (0.67) | KDM4EMAPTMAPK1HTTLMNA | |
| SCHEMBL13742098 | 0.77 | MRGPRX4 (0.56) | KDM4ELMNANR1H4FFAR1 | |
| SCHEMBL4512565 | 0.76 | PTGDR2 (0.48) | NR1H4 | |
| SCHEMBL13742610 | 0.75 | FFAR1 (0.57) | KDM4EPPARGPPARDPPARANR1H4 | |
| SCHEMBL4496289 | 0.75 | PTGDR2 (0.55) | MAPTMAPK1L3MBTL1 | |
| SCHEMBL8329343 | 0.75 | LTA4H (0.60) | KMT2APPARGPPARDPPARAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1585511-A4 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1585511-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | Tularik, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | AMGEN INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004058164-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | KDM4E 2510/4885MAPT 1718/4885MAPK1 1615/4885 |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | KDM4E 2510/4885MAPT 1718/4885MAPK1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.